Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;9(7):103484.
doi: 10.1016/j.esmoop.2024.103484. Epub 2024 Jun 19.

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

M C Cursano  1 , A A Valsecchi  2 , F Pantano  3 , M Di Maio  2 , G Procopio  4 , A Berruti  5 , F Bertoldo  6 , M Tucci  7 , U De Giorgi  1 , D Santini  8 ; Meet-URO and AIOM experts
Collaborators, Affiliations

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

M C Cursano et al. ESMO Open. 2024 Jul.

Abstract

Background: Prostate cancer (PCa) treatments are associated with a detrimental impact on bone health (BH) and body composition. However, the evidence on these issues is limited and contradictory. This consensus, based on the Delphi method, provides further guidance on BH management in PCa.

Materials and methods: In May 2023, a survey made up of 37 questions and 74 statements was developed by a group of oncologists and endocrinologists with expertise in PCa and BH. In June 2023, 67 selected Italian experts, belonging to the Italian scientific societies Italian Association of Medical Oncology and Italian Network for Research in Urologic-Oncology (Meet-URO), were invited by e-mail to complete it, rating their strength of agreement with each statement on a 5-point scale. An agreement ≥75% defined the statement as accepted.

Results: In non-metastatic hormone-sensitive PCa, the panel agreed that androgen deprivation therapy (ADT) alone implies sufficient fracture risk to warrant antifracture therapy with bone-targeting agents (BTAs) for cancer treatment-induced bone loss (CTIBL) prevention (79%). Therefore, no consensus was reached (48%) for the treatment with BTAs of patients receiving short-term ADT (<6 months). All patients receiving active treatment for metastatic hormone-sensitive PCa (75%), non-metastatic castration-resistant PCa (89%) and metastatic castration-resistant PCa (mCRPC) without bone metastases (84%) should be treated with BTAs at the doses and schedule for CTIBL prevention. All mCRPC patients with bone metastasis should be treated with BTAs to reduce skeletal-related events (94%). In all settings, the panel analyzed the type and timing of treatments and examinations to carry out for BH monitoring. The panel agreed on the higher risk of sarcopenic obesity of these patients and its correlation with bone fragility.

Conclusions: This consensus highlights areas lacking major agreement, like non-metastatic hormone-sensitive prostate cancer patients undergoing short-term ADT. Evaluation of these issues in prospective clinical trials and identification of early biomarkers of bone loss are particularly urgent.

Keywords: AIOM; Meet-URO; body composition; bone health; consensus; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure DS reports fee from advisory boards by AstraZeneca, Lilly, Daiiki-Sanchio, Astellas, Janssenn, Recordati, Gilead, Pfizer, MSD, Novartis, BMS, Roche, EISAI and Ipsen. MDM reports honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Roche, GlaxoSmithKline, Amgen, Merck, Takeda for consultancy or participation to advisory boards; direct research funding from Tesaro/GlaxoSmithKline; institutional funding for work in clinical trials/contracted research from Beigene, Exelixis, MSD, Pfizer and Roche. UDG: consulting or advisory role for Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, DompéFarmaceutici, Eisai, Ipsen, Janssen, Merck KgaA, MSD, Novartis and Pfizer; research funding (institution) from AstraZeneca, Roche and Sanofi; and travel accommodations from AstraZeneca, Ipsen and Pfizer. All other authors have declared no conflicts of interest.

References

    1. I Numeri del Cancro in Italia, 2021. https://www.aiom.it/wp-content/uploads/2021/10/2021_NumeriCancro_web.pdf Available at.
    1. Rhee H., Gunter J.H., Heathcote P., et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2015;115(suppl 5):3–13. - PubMed
    1. Nguyen P.L., Alibhai S.M., Basaria S., et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;5:825–836. - PubMed
    1. Wang A., Obertová Z., Brown C., et al. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer. 2015;15:837. - PMC - PubMed
    1. Taylor L.G., Canfield S.E., Du X.L. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11):2388–2399. - PubMed

Substances